Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Medtronic
Citi
Chinese Patent Office
Dow
Farmers Insurance
McKinsey
Argus Health
Healthtrust

Generated: November 16, 2018

DrugPatentWatch Database Preview

Gemini Labs Llc Company Profile

« Back to Dashboard

What is the competitive landscape for GEMINI LABS LLC, and what generic and branded alternatives to GEMINI LABS LLC drugs are available?

GEMINI LABS LLC has two approved drugs.



Summary for Gemini Labs Llc
US Patents:0
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Gemini Labs Llc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-001 Dec 22, 1997 AB RX Yes No ➤ Sign Up ➤ Sign Up
Gemini Labs Llc OXANDRIN oxandrolone TABLET;ORAL 013718-002 Nov 5, 2001 DISCN Yes No ➤ Sign Up ➤ Sign Up
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-003 Dec 22, 1997 AB RX Yes Yes ➤ Sign Up ➤ Sign Up
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-002 Dec 22, 1997 AB RX Yes No ➤ Sign Up ➤ Sign Up
Gemini Labs Llc OXANDRIN oxandrolone TABLET;ORAL 013718-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Gemini Labs Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gemini Labs Llc OXANDRIN oxandrolone TABLET;ORAL 013718-002 Nov 5, 2001 6,090,799 ➤ Sign Up
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-003 Dec 22, 1997 4,873,080 ➤ Sign Up
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-003 Dec 22, 1997 5,312,924 ➤ Sign Up
Gemini Labs Llc PRANDIN repaglinide TABLET;ORAL 020741-002 Dec 22, 1997 5,216,167 ➤ Sign Up
Gemini Labs Llc OXANDRIN oxandrolone TABLET;ORAL 013718-001 Approved Prior to Jan 1, 1982 5,872,147 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for GEMINI LABS LLC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 2.5 mg and 10 mg ➤ Subscribe 2006-06-19
➤ Subscribe Tablets 0.5 mg, 1 mg and 2 mg ➤ Subscribe 2005-02-10
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Moodys
Daiichi Sankyo
Healthtrust
Accenture
Baxter
Chinese Patent Office
Cantor Fitzgerald
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.